Spine BioPharma — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Spine BioPharma is a private, pre-revenue biotech focused on a critical unmet need: non-opioid, non-surgical treatments for chronic low back pain caused by degenerative disc disease (DDD). The company's pipeline is centered on SB-01, a first-in-class, intradiscally injected therapeutic that has advanced to a Phase 3 clinical trial. Operating with a lean structure, Spine BioPharma leverages partnerships with pharmaceutical companies, scientists, and clinicians to advance its mission of improving quality of life for millions of patients suffering from debilitating spinal conditions.

Degenerative Disc DiseaseChronic Low Back Pain

Technology Platform

Focused on intradiscal injection of novel biologics (potentially RNA/gene therapy based) for targeted, local treatment of disc pathology.

Opportunities

The massive, underserved market for chronic low back pain and the strong push for non-opioid therapies create a powerful tailwind.

Success with SB-01 could establish a new treatment paradigm, positioning the company as a leader in disease-modifying spine therapeutics.

Risk Factors

High clinical risk of Phase 3 failure for its sole lead asset, SB-01.

Significant regulatory and reimbursement challenges await even with approval.

The company faces financing risk as a private, pre-revenue entity funding an expensive late-stage trial.

Competitive Landscape

Competition includes generic pain medications, medical device companies for spinal implants and injection devices, and other biotechs developing biologic/regenerative therapies for musculoskeletal pain. SB-01's intradiscal, disease-modifying approach aims to carve out a unique niche.

More companies in RNA Therapeutics (non-mRNA) →More companies in United States →